Survival Estimates after Stopping Sorafenib in Patients with Hepatocellular Carcinoma: NEXT Score Development and Validation
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Survival Estimates after Stopping Sorafenib in Patients with Hepatocellular Carcinoma: NEXT Score Development and Validation
Authors
Keywords
-
Journal
Gut and Liver
Volume 11, Issue 5, Pages 693-701
Publisher
The Editorial Office of Gut and Liver
Online
2017-06-27
DOI
10.5009/gnl16391
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib
- (2015) Massimo Iavarone et al. HEPATOLOGY
- Sorafenib therapy for hepatocellular carcinoma with extrahepatic spread: Treatment outcome and prognostic factors
- (2015) Won Sohn et al. JOURNAL OF HEPATOLOGY
- Determinants of Survival After Sorafenib Failure in Patients With BCLC-C Hepatocellular Carcinoma in Real-World Practice
- (2015) I-Cheng Lee et al. MEDICINE
- EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
- (2015) et al. JOURNAL OF HEPATOLOGY
- Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy: A Korean multicenter study
- (2014) Sangheun Lee et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Alternative Response Criteria (Choi, European Association for the Study of the Liver, and Modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in Patients With Advanced Hepatocellular Carcinoma Treated With Sorafenib
- (2014) M. Ronot et al. ONCOLOGIST
- Sorafenib: from literature to clinical practice
- (2013) V. Di Marco et al. ANNALS OF ONCOLOGY
- Postprogression survival of patients with advanced hepatocellular carcinoma: Rationale for second-line trial design
- (2013) Maria Reig et al. HEPATOLOGY
- Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study
- (2013) Josep M. Llovet et al. JOURNAL OF CLINICAL ONCOLOGY
- Worse outcome of sorafenib therapy associated with ascites and Child-Pugh score in advanced hepatocellular carcinoma
- (2013) Hwi Young Kim et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Prognosis of patients with advanced hepatocellular carcinoma who failed first-line systemic therapy
- (2013) Yu-Yun Shao et al. JOURNAL OF HEPATOLOGY
- Efficacy of Sorafenib Monotherapy versus Sorafenib-Based Loco-Regional Treatments in Advanced Hepatocellular Carcinoma
- (2013) Sangheun Lee et al. PLoS One
- Hepatocellular carcinoma
- (2012) Alejandro Forner et al. LANCET
- Global cancer statistics
- (2011) Ahmedin Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Significance of Alpha-Fetoprotein and Des-γ-Carboxy Prothrombin in Patients with Hepatocellular Carcinoma Undergoing Hepatectomy
- (2009) Kentaroh Yamamoto et al. ANNALS OF SURGICAL ONCOLOGY
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started